Compare BOTJ & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOTJ | PLYX |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.0M | 112.7M |
| IPO Year | 2015 | 2025 |
| Metric | BOTJ | PLYX |
|---|---|---|
| Price | $27.30 | $1.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 40.6K | 27.6K |
| Earning Date | 11-02-2026 | 11-14-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | 13.71 | ★ 77.53 |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $4,273,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.17 | ★ N/A |
| Revenue Growth | ★ 6.74 | N/A |
| 52 Week Low | $15.50 | $1.84 |
| 52 Week High | $28.56 | $10.93 |
| Indicator | BOTJ | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 39.82 | 34.31 |
| Support Level | $26.08 | N/A |
| Resistance Level | $28.41 | $2.18 |
| Average True Range (ATR) | 0.71 | 0.10 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 10.05 | 3.26 |
Bank of the James Financial Group Inc is a bank holding company that provides retail and commercial banking, deposit services, lending services, mortgage brokerage services, and other banking services. The company provides a range of deposit services including checking accounts, savings accounts and other time deposits of various types, ranging from daily money market accounts to longer-term certificates of deposit. It offers various types of secured and unsecured consumer loans, including personal loans, lines of credit, overdraft lines of credit, automobile loans, installment loans, demand loans, and home equity loans. It operates three business segments community banking; mortgage banking, and investment advisory services.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.